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Plasminogen deficiency is an ultra-rare multisystem disorder charac-terized by the development of fibrin-rich pseudomembranes onmucous membranes. Ligneous conjunctivitis, which can result in
vision impairment or loss, is the most frequent symptom reported.
Affected systems may also include the respiratory tract, oropharynx,
female reproductive tract, gingiva, middle ear, renal collecting system,
skin and central nervous system. Untreated, plasminogen deficiency may
result in significant reduction in quality of life and morbidity with poten-
tial life-threatening complications. Non-specific therapies are inadequate
and plasminogen concentrates are not commercially available. The cur-
rent understanding of plasminogen deficiency and management of disease
symptoms and its progression are based on case reports/series and two
small clinical trials. To date there has never been a comprehensive, inter-
national study to examine the natural history or optimal therapeutic inter-
vention; knowledge gaps include identification of contributing factors and
triggers of disease manifestations, inability to predict disease course, and
insufficient real-world data for use of therapeutics. We have created an
international, observational study (HISTORY) in a large cohort of persons
with plasminogen deficiency and first-degree family members to address
these gaps and to advance knowledge and care. HISTORY will build upon
the established relationship between the Indiana Hemophilia and
Thrombosis Center and the Fondazione Angelo Bianchi Bonomi, IRCCS
Ca’ Granda Ospedale Maggiore Policlinico - University of Milan and will
utilize a modified version of the Prospective Rare Bleeding Disorders
Database (PRO-RBDD). A biorepository containing samples from sub-
jects with plasminogen deficiency will be established. This article
describes the rationale behind the study and efforts towards its goals.
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ABSTRACT
Introduction
Diseases are defined as rare if they affect fewer than 200,000 people in the
United States of America (USA) or fewer than 1 in 2,000 in the European Union;
there are estimated to be approximately 6,500 clinically distinct rare diseases
across all medical specialties.1 Given the large number of diseases meeting this
broad classification, the term ‘ultra-rare disease’ has emerged to describe the rarest
of these disorders; this phrase is not well defined, but in the United Kingdom (UK)
it has come to mean fewer than 1,000 patients in that country (approximately 1 in
65,000). These diseases pose unique considerations for the researcher, clinician
and patient; these range from an understanding of the natural history of the dis-
ease and accurate diagnosis, to safe and effective treatment options and availabil-
ity of knowledgeable specialists.
Randomized and large prospective clinical trials are often not feasible for ultra-
rare diseases as the limited number of eligible patients and phenotypic hetero-
geneity affect recruitment, interpretation of data and
applicability of conclusions to the larger real-world popu-
lation of patients; in many cases it may not be possible to
design a clinical trial accurately because of insufficient
knowledge of the disease.2 Instead clinicians have often
relied on personal experience, case studies/series and
patient registries to understand the natural history of
these diseases and to collect data on therapeutic interven-
tions and patient outcomes. Patient registries may be
national, regional or international, each with its own
advantages and disadvantages. The value of international
patient registries in rare diseases has long been recog-
nized; however, given the large number of rare diseases
and the small number of affected patients, funding oppor-
tunities are frequently limited, particularly for long-term
maintenance.1
Some diseases are so rare that many clinicians may
never see a case; for example, plasminogen deficiency
(PLGD) is an ultra-rare disease with an estimated preva-
lence of approximately 1.6 per million population. Most
commonly it presents as ligneous conjunctivitis, an
extravascular accumulation of fibrin-rich, woody (lig-
neous) pseudomembranes on the mucous membrane of
the eye; it can also manifest on other mucous mem-
branes, and as a life-long, systemic disease impacting
multiple systems either intermittently or continuously.
No specific therapies are approved by the Food and Drug
Administration or European Medicines Agency and non-
specific treatments are inadequate.
Current knowledge of PLGD stems from case reports
and small series; systematic prospective data collection
coupled with serial biological samples collected from per-
sons with PLGD and first-degree family members has not
been performed. Knowledge gaps include identification
of contributing factors to and triggers of disease manifes-
tations, inability to predict disease course, and insuffi-
cient real-world data for individualized use of potential
new therapeutics. To address unmet needs, a retrospec-
tive and prospective data collection system of a large
cohort of people with PLGD and their family members
has been developed to define the natural history of PLGD
and is entitled Hypoplasminogenemia: An International
RetroSpecTive and PrOspective CohoRt StudY (HISTORY).
HISTORY addresses key gaps in the knowledge about the
natural history of PLGD and builds on the
productivity/infrastructure of the established collabora-
tive efforts of research teams at the Indiana Hemophilia
and Thrombosis Center (IHTC), the Fondazione Angelo
Bianchi Bonomi, IRCCS Ca’ Granda Ospedale Maggiore
Policlinico of Milan (IRCCS) and the University of Milan
(UNIMI).  Phenotypic data combined with genetic and
advanced laboratory testing will be used to investigate
disease course predictors and evaluate/elucidate pheno-
typic relationships. A specimen biorepository will serve
as a resource for further analyses. Overarching study
goals are to analyze phenotypic heterogeneity, to identify
markers to predict disease course, and to develop
improved methods to utilize new therapeutics.  
Plasminogen deficiency
Congenital PLGD is an autosomal recessive disorder
caused by mutations in PLG that result in functionally defi-
cient and/or reduced levels of circulating plasminogen.3 An
epidemiological study performed in the UK observed a
0.26% prevalence of asymptomatic heterozygous PLGD;4-6
similar prevalences of heterozygous PLGD have been
reported in other countries.7-9 The UK data suggest that the
prevalence of individuals with symptomatic PLGD
(homozygous/compound heterozygous) is 1.6 per million
population;10,11 there are estimated to be 500 symptomatic
people with PLGD in the USA and 12,000 worldwide.
Based on experience with other rare bleeding disorders, a
higher prevalence of PLGD is likely to occur in regions
where consanguineous marriages are more common;11,12 for
this reason, a national study would likely misstate the true
prevalence and phenotypic diversity of the disease. An
increased number of females are reported to be sympto-
matic compared to males (ratio of 1.27-1.88:1).12,13
People with PLGD may exhibit a multi-organ systemic
disease that commonly manifests as the extravascular
accumulation of fibrin-rich, woody (ligneous)
pseudomembranes on mucous membranes. PLGD is a
lifelong disease, although the most severe symptoms are
observed in infants and children.3,14 Ligneous conjunctivi-
tis is the most common disease symptom (81% preva-
lence);3 pseudomembrane growth may be triggered by a
local infection or injury and can result in impairment or
loss of vision if untreated and/or persistent.3,11
Approximately one-third of people with PLGD have
corneal involvement with potential for blindness,11,12 and
30% present with ligneous gingivitis resulting in peri-
odontal destruction and tooth loss.3,12,13 Other common
symptom locations include the respiratory tract (20%),
ears (14%), female genitourinary tract (9%), and kidneys
(4%).3,11,15-18
Lesions are often inflamed and painful and can compro-
mise organ function, resulting in life-threatening condi-
tions including renal and respiratory failure (e.g., tracheo-
bronchial lesions).11,18 Central nervous system complica-
tions have been noted, including Dandy-Walker malfor-
mation and occlusive hydrocephalus12 in 14% of children
due to fibrin deposition in the cerebral ventricular system;
shunts used to drain cerebrospinal fluid are prone to
occlusion or poor peritoneal absorption, leading some
neurosurgeons to recommend ventriculocholecystic
shunts.19 In women, dysmenorrhea, abnormal menses,
dyspareunia, and infertility have been reported.15 Wound
healing may be severely impaired.20 Lesions in the middle
ear may result in hearing loss.11 Although the initial case
of PLGD was documented in a patient with recurrent
venous thromboembolism, an association between PLGD
and increased thrombotic risk has not been demonstrat-
ed.10,21 Patients may suffer substantial morbidity and mor-
tality and experience reduced quality of life and educa-
tion/work potential.14
Surgical removal of lesions often results in accelerated
pseudomembrane regrowth compounding clinical mor-
bidity.22 Case reports describing use of topical or systemic
heparin, corticosteroids, cyclosporine, azathioprine,
hyaluronidase, α-chymotrypsin, oral contraceptives, war-
farin, and amniotic membrane placement have been pub-
lished; these approaches show inconsistent success
(examples of therapies utilized are shown Table 1).13,23-29
Fresh-frozen plasma has been reported to be successful in
some cases when eye drops, subconjunctival injection
and/or intravenous infusions are utilized;30,31 however, as
fresh-frozen plasma contains low concentrations of plas-
minogen, volume overload may occur when the intra-
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venous route of administration is used. Infusion reac-
tions, time required for administration and need for
repeated infusions may also limit intravenous use of
fresh-frozen plasma.
Several case studies have reported on topical ophthal-
mological application of plasminogen for the treatment of
ligneous conjunctivitis. Watts et al. noted that following
surgical removal of pseudomembranes, plasminogen eye
drops administered every 2 h prevented regrowth; a
maintenance dose every 6 h prevented symptoms for
over 1 year.32 Similarly, Pons et al. reported resolution of
ligneous conjunctivitis with administration of plasmino-
gen eye drops; in this patient, multisystem manifestations
subsequently developed that could not be treated.33 An
interim analysis of a phase II/III clinical trial studying
ophthalmological plasminogen (2 drops, 4-12 times daily)
was reported by Nakar et al.34 Ten out of 11 subjects
(91%) experienced full regression of ophthalmological
lesions and/or absence of recurrence following surgical
excision (the 11th subject was withdrawn because of non-
compliance). This clinical trial (NCT01554956) is ongo-
ing.
Shapiro et al. have reported results from a phase II/III
clinical trial (NCT02690714) investigating the use of an
intravenous plasma-derived plasminogen concentrate (6.6
mg/kg iv, every 2-4  days depending on individual phar-
macokinetic profile).14 All 14 subjects achieved trough
plasminogen levels at least 10% above baseline; all preex-
isting clinical manifestations of PLGD (including lesions
on the conjunctiva, gingiva, nasopharynx, bronchus,
colon, kidney, cervix, and vagina) resolved or improved.
An amended biologics license application is expected to
be filed with the Food and Drug Administration for this
product in the first half of 2020.
The rarity of PLGD results in frequent mis- and delayed
diagnoses by professionals lacking specialist knowledge.
Difficulty with diagnosis and disease rarity have con-
tributed to an inability to document the natural history,
develop clinical guidelines, and optimize treatment regi-
mens. An exclusively USA-based registry would be of
limited value as this would restrict recruitment and might
fail to identify the full spectrum of the disorder.
Therefore, an international effort has been undertaken to
gain unique and broad insights into the disease, its pro-
gression and optimal treatment.
Registries in rare coagulation disorders
Hemophilia A and B are two of the more common rare
coagulation disorders; they affect approximately 1:5,000
and 1:30,000 persons, respectively. Our current under-
standing of hemophilia and the wide availability of spe-
cialized care and therapeutic options are a result of the
many clinical trials and patient registries that have been
developed over the years. 
Patient registries in hemophilia may be national,
regional or international. O’Mahony et al. noted that
27/35 European countries had their own national hemo-
philia patient registry and some countries have multiple
national registries operated by different organizations
with little consideration given to interoperability.35,36 This
lack of interoperability and the variability in
inclusion/exclusion criteria for enrolled subjects, defini-
tions utilized, data collected, and different goals of these
national registries all limit the pooling of data to the detri-
ment of all stakeholders. One example of the issues asso-
ciated with multiple registries pursuing similar goals may
be observed in those that examined the determinants of
hemophilic inhibitor development and predictors of
immune tolerance induction success: different registries
reported different conclusions based on the patients
enrolled and the data collected.37 Ideally, collaboration
between registries and harmonization of data collection
are necessary to achieve minimal datasets for advance-
ment of shared clinical goals in these rare disorders.38,39
Advantages and disadvantages of national, regional and
international registries are highlighted in the following
examples.
The American Thrombosis and Hemostasis Network
The American Thrombosis and Hemostasis Network
(ATHN) collects data on patients in the USA with rare
coagulation disorders. The centralized database and stan-
dardized definitions for data entry enhance research and
clinical goals; these include the generation of the largest
genetic hemophilia repository (My Life, Our Future) and
the surveillance of over 80,000 persons with rare coagula-
tion disorders (Community Counts).40,41 Despite these
successes, Gupta et al. noted limitations in data collection;
for example, of the known 3,626 patients with an ultra-
rare coagulation disorder, less than 11% had been includ-
ed in the Community Counts registry.39 Furthermore, the
strictly USA-centric dataset may limit wider applicability
of results to other countries with different medical
resources and population diversity. These limitations
highlight why efforts to create a comprehensive ultra-rare
coagulation disorder registry in a single country may be
less successful than desired. 
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Table 1. Examples of published therapies for the most common mani-
festations of plasminogen deficiency, ligneous conjunctivitis and lig-
neous gingivitis. 
Therapy*                                                    LC                             LG
                                                           [reference]                [reference]
Fresh-frozen plasma                                        [31]                                [22]
Plasminogen concentrate                            [14,34]                             [14]
Anticoagulants
       Heparin                                                         [23]
      Warfarin                                                                                               [28]
      Argatroban                                                   [33]
Immunosuppressants
       Corticosteroids                                          [23]                                [10]
       Azathioprine                                                [11]
       Cyclosporine A                                         [24,25]
Oral contraceptives                                          [27]
Thrombolytic
      Anistreplase                                                [10]
Hyaluronidase                                                    [26]
Alpha chymotrypsin                                          [26]
Mast cell stabilizer
       Cromoglicic acid                                         [11]
Anti-proliferative agent
       Mitomycin C                                                 [11]
LC: ligneous conjunctivitis; LG: ligneous gingivitis. *Not all reported therapeutic results
have been shown to be reproducible.
European Network of Rare Bleeding Disorders
The Rare Bleeding Disorders Database (RBDD) project
was established at UNIMI in 2004 to organize and ana-
lyze clinical, genetic and treatment data on rare bleeding
disorders, including deficiencies of fibrinogen and factors
II, V, combined V and VIII, VII, X, XI and XIII. In 2007,
this database was modified to include the use of a web-
based application to create the retrospective European
Network of Rare Bleeding Disorders (EN-RBD) project.42
Data on 592 patients from 11 European countries were
included. These data led to the first authoritative under-
standing of the relationship between coagulation factor
activity level and clinical bleeding severity in ultra-rare
bleeding disorders; in turn this resulted in the develop-
ment of a new severity classification system for bleeding
symptoms.43
Prospective Rare Bleeding Disorders Database
To overcome limitations of retrospective data collec-
tion, EN-RBD was subsequently modified to incorporate
prospective data on patients. This registry, the
Prospective Rare Bleeding Disorders Database (PRO-
RBDD), enrolled patients from 62 centers in Europe, Asia,
the Middle East, the Americas, Africa, and Oceania.44 The
greatly expanded international network of participating
centers was considered essential for a registry focusing on
diseases for which the prevalence may approach 1 per
million population; this extended outreach may permit
increased and more rapid enrollment, and greater pheno-
typic and genetic diversity. 
The aims of PRO-RBDD are a more accurate determi-
nation of the prevalence of rare bleeding disorders, the
incidence of bleeding episodes, the use of treatment prod-
ucts, and the optimization of clinical management.
Currently, subjects with deficiencies in fibrinogen and
factors V, V/VIII, XI and XIII are being enrolled in PRO-
RBDD with phenotype/genotype evaluation performed
at a central laboratory to ensure consistency. Initial results
have helped define minimal factor XIII plasma levels (15
IU/dL) necessary to prevent spontaneous major bleeding
in people with factor XIII deficiency;45 this observation
highlights the importance of registry data to clinical prac-
tice.  
The plasminogen deficiency registry (HISTORY project)
HISTORY is an extension of PRO-RBBD; it is an obser-
vational cross-sectional study that will contain both retro-
spective and prospective data from an international pop-
ulation of people with PLGD and their immediate family
members. PRO-RBDD was selected as the ideal infra-
structure for HISTORY as previously gained experience,
proven track-record and established collaborations should
ensure timely and efficient achievement of study goals.
Retrospective data will be collected for 1 year prior to
study entry; prospective data will be collected for each
subject for a 3-year on-study period. 
The overarching goals driving data analysis are devel-
opment of disease severity categories, disease course pre-
dictors and need for specific surveillance in particular sub-
populations, and treatment algorithms and recommenda-
tions to guide clinical care and management. As such, the
registry design will allow collection of general informa-
tion about each subject’s health, with specific details
regarding: original diagnosis (age, reason for screening);
phenotype and genotype analysis; type, site and number
of clinical manifestations indicative of pseudomembrane
formation; detailed information on type, intensity, and
duration of any prophylactic treatment, frequency and
dose; type, frequency and dose of therapy administered
to treat acute or chronic pseudomembranes; laboratory
parameters; use of concomitant therapy; detailed infor-
mation of management of surgical procedures; obstetric
data; and complications associated with treatment.
The coordinating centers for this study are the IHTC
and IRCCS/UNIMI. The IHTC is enrolling subjects from
North, South and Central America and IRCCS/UNIMI is
enrolling subjects from the rest of the world. The data-
base will be located at UNIMI and specimens will be
stored at the IHTC and/or IRCCS/UNIMI biorepositories.
Safeguards have been implemented to protect confiden-
tial medical information to meet national regulations; all
clinical information and biological samples will be stored
in accordance with the Health Insurance Portability and
Accountability Act of 1996 or General Data Protection
Regulation in the USA and Europe, respectively.
Clinical study protocols and laboratory manuals have
been developed and approved by local institutional
review boards. HISTORY will be conducted in compli-
ance with Good Clinical Practice as stated in the
Declaration of Helsinki; it is registered at clinicaltrials.gov
(NCT03797495).
Patient recruitment and study visits
There is currently no authoritative natural history study
for PLGD; HISTORY is a 4-year study (Figure 1A) that
will be the first international effort to define the natural
history of this disorder by reviewing retrospective and
prospective data from up to 100 probands and their first-
degree family members (approximately 500 subjects in
total). Asymptomatic family members will be recruited in
addition to symptomatic individuals. Asymptomatic fam-
ily members are not routinely tested for PLGD; study
testing will provide a unique opportunity to prospectively
monitor any newly diagnosed patients to investigate the
deficiency prior to symptom development. The inclusion
of heterozygous family members may additionally reveal
the relationship between minimal plasminogen activity
levels and natural history. Inclusion and exclusion criteria
are listed in Table 2. 
The registry will include a minimum of seven data
entry points per subject (baseline and every 6 months for
3 years) with data also collected at other non-scheduled
visits (Figure 1B and Table 3). Retrospective baseline data
(demographic and clinical history for 1 year prior to
enrollment) will be collected at each study site, with
prospective follow-up data acquired by telephone if an
in-person visit is not required. In-person evaluation will
occur in cases of suspected clinical manifestations indica-
tive of pseudomembranes or other intermittent medical
events including pregnancy. Laboratory evaluation and
physical examination will be performed at baseline and at
study termination. 
To accelerate recruitment and meet the study objectives
efficiently, PLGD patients/families/providers held within an
IHTC tracking system (~50 probands) will be contacted to
determine interest in the study, as will authors of published
literature on cases/series of PLGD. Advertisements will be
placed in scientific journals that focus on diseases for which
clinicians may interface with people with PLGD.
Furthermore, an outreach program using social media, a
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dedicated website (www.plgdeficiency.com), presentations at
international meetings, and direct contact with interested
colleagues will be pursued. Study coordinators at
IRCCS/UNIMI will contact their established treatment cen-
ter network throughout the world. In addition to hematol-
ogists, specialists including gynecologists and ophthalmolo-
gists will also be contacted; these healthcare professionals
may be the first to observe a patient with PLGD. A multi-
disciplinary approach including such specialists is essential
to improve overall awareness and understanding of the dis-
order; it may also prevent the loss of patients to follow-up
by a hematologist as some patients may continue treatment
outside of a specialist hematology center. As PLGD may
affect different systems throughout life, the investigators
are enrolling subjects across a wide range of ages, countries,
phenotypes and genotypes. People with PLGD are motivat-
ed to participate in studies to advance PLGD understanding
as few study opportunities exist.
To date, 26 centers from 12 countries have agreed to par-
ticipate in HISTORY; 51 subjects (24 probands and 27
first-degree family members) are currently enrolled in the
study. Demographic data for these 51 subjects are shown
in Table 4. Initial results have identified asymptomatic
siblings with PLGD; these subjects are being monitored
to understand the factors that trigger initial symptom
development. 
Therapeutic interventions
Regular monitoring and individualization of therapy is
required for people with PLGD as there is currently no
compelling evidence that a patient’s clinical course can be
predicted from their plasminogen activity level or genetic
defect.12 Similarly, if a patient presents with ligneous con-
junctivitis, the likelihood of developing multisystem dis-
ease cannot be predicted; it is unknown what routine
scans should be performed, what surveillance methods
A.D. Shapiro et al.
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Figure 1. Overall study timeline and scheduled study visits. (A) The 4-year study plan includes a 1-year enrollment period and a maximum 3-year on-study period for
each subject enrolled. Retrospective clinical data for 1 year prior to study enrollment will also be collected. (B) The initial baseline visit will include informed consent,
demographics, screening, laboratory investigations, genetic testing, medical examination and history, and a 1-year retrospective collection of relevant clinical data.
Subsequent study visits will occur every 6 months and will include a medical history review; the closeout visit will occur at the 3-year time point. See also Table 3.
Table 2. Inclusion and exclusion criteria for enrollment in HISTORY
Inclusion criteria                                                                                           Exclusion criteria
Males or females with plasminogen deficiency diagnosed locally                        Any psychiatric disorder, other mental disorder, or any other medical 
with plasminogen activity levels <50% OR first-degree family members           disorder that impairs the subject’s ability to give informed consent or to
of a person diagnosed with plasminogen deficiency  (to include parents,         comply with the requirements of the study protocol (unless a caregiver 
siblings, half-siblings)                                                                                                       or authorized representative is willing to provide consent/assent)
All ages eligible                                                                                                                   Previous organ transplant recipient
Available clinical history and treatment for at least 1 year prior                           Refusal to provide informed consent
to entry except for infants <1 year of age
Willingness to provide samples for analysis including DNA, plasma etc.             Special patient populations, including prisoners or those who are deemed 
                                                                                                                                                 medically or cognitively unsuitable for research by their treating physician
Willingness to participate in prospective follow-up for up to 3 years                   Inability to obtain a blood sample due to poor or limited venous access
A
B
should be used, or how frequently clinical visits should
occur to monitor for symptoms to ensure early interven-
tion and prevent sequelae. Furthermore, it is unknown if
treatment should be lifelong, intermittent, or may be
withdrawn over time and how this varies by patient, dis-
ease severity, and affected system. 
All non-specific therapeutic interventions to treat acute
and chronic manifestations of PLGD will be recorded,
along with efficacy, safety and complications. Specific
treatments, including ophthalmological plasminogen
drops and systemic intravenous plasminogen replace-
ment therapy are currently under clinical investigation;14,34
any use of these investigational agents will also be record-
ed. Currently, data to support wider real-world optimal
therapeutic regimens are lacking. There are no standard
dosing regimens for intravenous plasminogen replace-
ment therapy and the required minimal plasminogen
plasma levels to treat or prevent specific manifestations
are unknown; treatment for each patient must be individ-
ualized based on their pharmacokinetic profile.14 HISTO-
RY will explore development of a population pharmaco-
kinetic model46 for the investigational intravenous plas-
minogen concentrate14 to estimate plasma levels and
adjust doses if symptoms emerge.  
Factors that correlate with disease expression and
severity
No screening test for PLGD exists; specific plasminogen
activity/antigen levels are required, but assays are not
uniformly available. This study will collect methodologi-
cal details of locally performed tests to review their diag-
nostic utility; testing will be repeated centrally to confirm
diagnosis and local assay utility. Peyvandi et al. demon-
strated that clotting level activity in some rare bleeding
disorders does not correlate with clinical bleeding severi-
ty.43 Published data suggest that this may also be true for
PLGD; therefore, global coagulation assays (including
thrombin generation, thromboelastography, simultane-
ous thrombin/plasmin generation and fibrinolytic poten-
tial)47-50 will be performed to evaluate their utility in phe-
notypic prediction and clinical management.
The true prevalence of PLGD is not well established
and likely depends on the population in any particular
region or country; similarly, the genetic alterations influ-
encing disease expression and severity are not well
defined. A genome-wide association study conducted by
Ma et al. determined genetic modifiers of plasminogen
levels in normal adults;51 the study revealed that four sin-
gle nucleotide polymorphisms were associated with vari-
ations in plasminogen levels. How these variations affect
the severity or progression of PLGD is unknown. The
PLG(K38E) mutation is known to result in a milder clini-
cal course;12,13 conversely, other mutations are known to
not be predictive (for example, in one family with the
conserved W597C mutation, one member was asympto-
matic, another had ligneous periodontitis, and a third had
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Table 3. Details of the study visits. 
Assessments                                               Baseline                     Year One                                  Year Two                         Year Three           Unscheduled*
                                                                                          6 months       12 months        18 months    24 months   30 months    36 months          
Informed consent                                                            X                                                                                                                                                                                     
Re-consent (if minor reaches 18 years)                                                                                                                                                                                                       X
Eligibility criteria                                                              X                                                                                                                                                                                     
Demographics                                                                   X                                                                                                                                                                                     
Laboratory investigations                                                                                                                                                                                                                                      
Plasminogen antigen level                                           X                                                                                                                                                             X                      
Plasminogen activity level                                            X                                                                                                                                                             X                    X
Genetic testing                                                               X                                                                                                                                                                                     
Family history                                                                    X                                                                                                                                                             X                      
Medical history                                                                                                                                                                                                                                                        
Initial comprehensive history/review                       X                                                                                                                                                                                     
of systems
Medical history since last visit (procedures,                                X                         X                             X                        X                      X                        X                    X
pregnancy, treatment, other symptoms or 
complications, etc.) 
Concurrent medications                                              X                     X                         X                             X                        X                      X                        X                    X
*Additional data will be collected at the time of an unscheduled visit for re-consent, illness, pregnancy (plasminogen activity level and banked plasma will be collected at con-
firmation of pregnancy, during the third trimester and at delivery), and development of lesions.
Table 4. Demographics of the initial 51 enrolled subjects. 
Demographics                             Subjects with         Unaffected family 
                                             plasminogen deficiency         members
Gender
    Male                                                               9                                      11
    Female                                                         15                                     16
Age
    <18 years                                                    14                                      8
    ≥18 years                                                     10                                     19
Ethnicity
    White                                                            21                                     22
    Hispanic/Latino                                           3                                        5
Consanguineous parentage
    Yes                                                                 0                                        0
    No                                                                 22                                     27
    Unknown                                                      2                                        0
Endogenous plasminogen activity
    Median (%)                                               18.5                                   n/a
    Range (%)                                                1 - 42                                  n/a
Endogenous plasminogen antigen
    Median (mg/dL)                                        3.4                                    n/a
    Range (mg/dL)                                        1 - 12                                  n/a
n/a: not applicable.
ligneous conjunctivitis).12 HISTORY will record the preva-
lence of different mutations in the affected and heterozy-
gote population and attempt to determine the relation-
ship between mutation and clinical penetrance hetero-
geneity; it will also examine polymorphisms that may
influence fibrinolytic capacity (e.g., in fibrinogen Aα and
plasminogen activator inhibitor 1).52 The enrollment of
relatives of people with PLGD may enable a refinement
of plasminogen activity levels observed in heterozygotes.
The registry will also incorporate environmental and
host-specific factors that may modify plasminogen levels
and/or disease symptoms. A study in healthy subjects
found that smoking contributes to plasma plasminogen
levels;51 it is not known whether this and other environ-
mental factors affect plasminogen plasma levels in patients
with PLGD. It is also not clear whether an environmental
trigger is required for symptom development and/or dis-
ease expression, or whether and, if so, how specific plas-
minogen antibodies develop. HISTORY will address some
of these unknown environmental/host factors.  
Plasminogen deficiency biorepository
Research involving human genetic or genomic informa-
tion analyzed in conjunction with personal or health data
has become increasingly important for untangling genet-
ic, lifestyle and environmental disease determinants. A
biorepository containing DNA, plasma, and serum will be
created; samples will be stored for up to 15 years. If
planned analyses are not revealing, stored samples will be
utilized to explore other biomarkers to elucidate a corre-
lation/prediction of phenotypic heterogeneity (e.g., poly-
morphisms in inflammatory markers, whole genome
analyses).
Data analyses 
To understand the impact of specific data on disease
expression, all collected data will be analyzed. Clinical
data on people with PLGD will be evaluated for categor-
ical characterization (i.e., asymptomatic, intermittently
symptomatic, and continuously symptomatic). The
probands’ age in each category will be analyzed to evalu-
ate age as a variable for symptom expression. Categories
will be modeled and analyzed against a range of variables
including gender, environmental factors, genetic studies,
laboratory coagulation parameters including specific and
exploratory global assays, and treatment administration.
Subjects with clinical symptoms will be evaluated for the
presence of individual affected sites versus multiple/sys-
temic symptoms, and also analyzed based on prior listed
variables. A descriptive analysis of symptoms reported by
physiological system will be performed and modeled
against study variables (levels, genetics, global assays, and
exploratory investigations) to determine whether any of
them are predictive. Symptoms and data will be reviewed
to determine whether severity categories can be estab-
lished. Urine analysis will be performed, as unpublished
data suggest that PLGD may be associated with microal-
buminuria; its prevalence in the wider PLGD population
is unknown. Data will be collected on subjects who
receive nonspecific and/or specific treatments if available;
they will be analyzed for therapeutic response, disease
control, and recurrence or emergence on therapy. 
Further details of the methods, procedures, and planned
analyses are reported in the Online Supplementary Material.
Conclusions
There is currently no central repository to collect and
analyze data from people with PLGD; clinicians rely on
case reports and individual experience to diagnose and
treat patients, resulting in treatment variability and less
than optimal outcomes. The HISTORY study may play a
substantial role in addressing these deficits by collecting
clinical, genetic, and laboratory data which will be ana-
lyzed to identify potential markers that can assist in dis-
ease course prediction and understanding heterogeneity
in phenotypic expression. This study may also enable the
development of standardized assays, the identification of
at-risk groups, and guidelines for non-specific and specific
therapies. 
To date, no other international team of dedicated
experts has been assembled to investigate the natural his-
tory of PLGD and fill knowledge gaps; HISTORY pro-
vides the first comprehensive effort to address this ultra-
rare disease. It is not possible for one center or country to
singlehandedly complete this study; all interested parties
are therefore strongly encouraged to view the study web-
site (www.plgdeficiency.com), participate if they know of or
care for anyone with PLGD or contact the authors direct-
ly to discuss potential involvement in this registry. Full
enrollment and patient diversity will benefit all those
with this disorder.
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